How GLP-1 Medications Actually Work
A plain-language look at what semaglutide, tirzepatide, and related drugs do inside the body, what the big trials showed, and where the science is still uncertain.
GLP-1 medications have become some of the most talked-about drugs in medicine. Names like semaglutide (sold as Wegovy and Ozempic) and tirzepatide come up constantly in conversations about weight, diabetes, and heart health. But the headlines rarely explain what these drugs are actually doing inside the body. This article walks through the mechanisms as described in the drug labels and peer-reviewed research, sticks closely to what the evidence supports, and flags honestly where the science is still uncertain.
What GLP-1 is, and what these drugs imitate
It's a hormone your body already makes — the drugs just keep the signal switched on a week at a time.
GLP-1, short for glucagon-like peptide-1, is a hormone your body already makes. According to the FDA-approved Wegovy label, GLP-1 is a physiological regulator of appetite and calorie intake, and its receptor is found in several areas of the brain involved in appetite regulation. GLP-1 medications are engineered to mimic this natural hormone, but in a longer-lasting form, so a single weekly dose keeps the signal switched on.
The label describes two broad effects. First, semaglutide lowers body weight and decreases how many calories a person eats, effects the label says are likely mediated by affecting appetite. It also produces more fat-mass loss than lean-mass loss. Second, the label notes that semaglutide delays gastric emptying, meaning food leaves the stomach more slowly.
How it changes appetite and blood sugar
Two levers at once: it quiets the brain's hunger signals, and it lets insulin rise only when blood sugar is already high.
For blood sugar, the FDA-approved Ozempic label explains that semaglutide reduces blood glucose by stimulating insulin secretion and lowering glucagon secretion, both in a glucose-dependent manner. That glucose-dependence matters: insulin is stimulated mainly when blood sugar is already elevated. That built-in limit is why, used on its own, the drug carries a lower risk of driving blood sugar dangerously low. The Ozempic label adds that its glucose-lowering also involves a minor delay in gastric emptying in the early period after eating.
For appetite, the more detailed picture comes from a peer-reviewed review in the Journal of Clinical Investigation. In a brain region called the arcuate nucleus of the hypothalamus, GLP-1 directly activates neurons that reduce appetite (the POMC/CART cells) and indirectly quiets neurons that drive hunger (the NPY/AgRP cells). GLP-1 receptors also sit in other appetite- and signal-processing areas of the brain and brainstem. The net effect described is reduced food intake.
These drugs do not force weight off the body. They turn down the biological drive to eat and let blood sugar regulate itself more gently.
An important honesty note here: much of this fine-grained brain circuitry is established primarily in rodent and other animal models. The Wegovy label itself attributes brain-region activation data to animal studies, and the review points out that effects on complex human behaviors are more complicated and involve multiple brain regions. In rodents, the full appetite-suppressing response to one GLP-1 drug required receptors in the central nervous system rather than the nerves connecting the gut to the brain. So the broad strokes are well supported, but the exact human wiring is not fully mapped.
The gastric-emptying effect deserves a similar caveat. In the diabetes label it is described as a minor delay in the early phase after a meal. How much this slowing contributes to long-term weight loss, versus the central appetite effect, is debated. The slowing is also thought to fade with continued dosing, so its role is best understood qualitatively rather than as a fixed number.
What the large trials actually showed
STEP, SURMOUNT, SELECT and SURMOUNT-OSA — the headline numbers, all measured on continued treatment plus lifestyle changes.
The mechanisms translate into measurable outcomes in randomized trials. Here are the headline results from the major studies, each on continued treatment combined with lifestyle changes:
- Weight loss (STEP 1)In 1,961 adults with overweight or obesity and without diabetes, once-weekly semaglutide 2.4 mg plus lifestyle intervention produced a mean body-weight change of -14.9% versus -2.4% with placebo at week 68. About 86.4% of the semaglutide group lost at least 5% of body weight, versus 31.5% on placebo.
- Weight loss (SURMOUNT-1)In 2,539 adults with obesity or overweight and without diabetes, tirzepatide produced mean weight loss of roughly 15% at 5 mg, 19.5% at 10 mg, and up to about 20.9% at 15 mg, versus about 3.1% with placebo at 72 weeks. Between 85% and 91% of tirzepatide-treated participants lost at least 5%, versus 35% on placebo.
- Heart outcomes (SELECT)In 17,604 adults with established cardiovascular disease and overweight or obesity but without diabetes, once-weekly semaglutide 2.4 mg reduced major adverse cardiovascular events (cardiovascular death, nonfatal heart attack, or nonfatal stroke) by about 20% (6.5% versus 8.0%; hazard ratio 0.80) over a mean of roughly 40 months.
- Sleep apnea (SURMOUNT-OSA)In two 52-week trials in adults with moderate-to-severe obstructive sleep apnea and obesity, tirzepatide (10 or 15 mg) cut the apnea-hypopnea index by 25.3 events per hour versus 5.3 with placebo among those not using a breathing machine, and by 29.3 versus 5.5 among those who were, alongside reductions in body weight, blood pressure, and an inflammation marker.
One crucial distinction runs through several of these results. Tirzepatide, used in SURMOUNT-1 and SURMOUNT-OSA, is not a pure GLP-1 drug. Its own trial documentation describes it as a receptor agonist that activates both the GIP receptor and the GLP-1 receptor. So those results reflect combined incretin-hormone signaling, not GLP-1 action alone, and are worth reading with that in mind under an article titled how GLP-1 medications work.
The biggest numbers on this page belong to tirzepatide — which is not a pure GLP-1 drug at all.
Limits, caveats, and open questions
The trial numbers assume you stay on the drug — and the safety story is not in the efficacy figures.
The trial numbers were achieved on ongoing active treatment plus lifestyle changes, not a short course. Substantial weight regain is common after stopping, which is why these are used as continuing therapy rather than a quick fix. The cardiovascular benefit in SELECT was shown in people who already had cardiovascular disease but no diabetes; its mechanism is not fully explained by weight loss alone, and the result should not be assumed to apply to lower-risk groups.
Stop the drug and much of the weight tends to return. These are treatments to stay on, not a course you finish.
These medications also carry class safety considerations not detailed in the evidence here, including predominantly gastrointestinal side effects, a boxed warning for thyroid tumors based on rodent data, gallbladder-related events, and aspiration-risk concerns before procedures tied to delayed gastric emptying. None of that is captured in the efficacy figures above, and any decision about these drugs belongs in a conversation with a licensed clinician.
- 01 FDA Wegovy (semaglutide) Prescribing Information, Sections 12.1/12.2 (via DailyMed), 2024 dailymed.nlm.nih.gov ↗Label basis for central appetite mechanism, greater fat-mass loss, and delayed gastric emptying.
- 02 FDA Ozempic (semaglutide) Prescribing Information, Section 12.1 (via DailyMed), 2025 dailymed.nlm.nih.gov ↗Label basis for glucose-dependent insulin and glucagon effects and early-phase gastric-emptying delay.
- 03 Peer-reviewed review of GLP-1 receptors in the brain and appetite circuitry (largely animal-model based).
- 04 Once-weekly semaglutide 2.4 mg vs placebo; -14.9% vs -2.4% at 68 weeks; 86.4% vs 31.5% achieved at least 5% loss (figures via ACC summary).
- 05 Jastreboff AM et al. (SURMOUNT-1), N Engl J Med, 2022 pubmed.ncbi.nlm.nih.gov ↗Tirzepatide (dual GIP/GLP-1) for obesity; treatment-regimen estimand -15.0%/-19.5%/-20.9% vs -3.1% placebo at 72 weeks (via PubMed abstract).
- 06 Semaglutide 2.4 mg cut major cardiovascular events ~20% (6.5% vs 8.0%; HR 0.80) in 17,604 patients with CVD and obesity, no diabetes, mean ~39.8 months (figures via ACC summary).
- 07 Tirzepatide for obstructive sleep apnea and obesity; AHI -25.3 vs -5.3 (no PAP) and -29.3 vs -5.5 (on PAP); dual GIP/GLP-1 agonist definition.
Wellness Wire Editorial
The Wellness Wire editorial team. Our explainers are researched from primary sources — clinical-trial reports and FDA labeling — and written for general education. They are not individually reviewed by a clinician and are not a substitute for medical advice.
